Feasibly of axitinib as first-line therapy for advanced or metastatic renal cell carcinoma: a single-institution experience in Japan.
about
Axitinib in metastatic renal cell carcinoma: single center experience.Axitinib induces DNA damage response leading to senescence, mitotic catastrophe, and increased NK cell recognition in human renal carcinoma cellsAxitinib in metastatic renal cell carcinoma: beyond the second-line setting.Contrast media enhancement reduction predicts tumor response to presurgical molecular-targeting therapy in patients with advanced renal cell carcinoma.
P2860
Feasibly of axitinib as first-line therapy for advanced or metastatic renal cell carcinoma: a single-institution experience in Japan.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Feasibly of axitinib as first- ...... stitution experience in Japan.
@ast
Feasibly of axitinib as first- ...... stitution experience in Japan.
@en
type
label
Feasibly of axitinib as first- ...... stitution experience in Japan.
@ast
Feasibly of axitinib as first- ...... stitution experience in Japan.
@en
prefLabel
Feasibly of axitinib as first- ...... stitution experience in Japan.
@ast
Feasibly of axitinib as first- ...... stitution experience in Japan.
@en
P2093
P2860
P1433
P1476
Feasibly of axitinib as first- ...... stitution experience in Japan.
@en
P2093
Atsushi Imai
Chikara Ohyama
Hayato Yamamoto
Kazuyuki Mori
Shingo Hatakeyama
Takahiro Yoneyama
Takuya Koie
Tohru Yoneyama
Yasuhiro Hashimoto
Yuki Tobisawa
P2860
P356
10.1186/S12894-015-0027-4
P577
2015-04-16T00:00:00Z